Dashboard
1
Poor long term growth as Net Sales has grown by an annual rate of 0.53% and Operating profit at 28.28% over the last 5 years
2
The company has declared Positive results for the last 3 consecutive quarters
3
With ROE of 15.34%, it has a fair valuation with a 3.28 Price to Book Value
4
Market Beating Performance
Stock DNA
Pharmaceuticals & Biotechnology
CNY 8,613 Million (Large Cap)
21.00
NA
1.78%
-0.38
15.34%
3.28
Revenue and Profits:
Net Sales:
405 Million
(Quarterly Results - Jun 2025)
Net Profit:
92 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-20.59%
0%
-20.59%
6 Months
-5.15%
0%
-5.15%
1 Year
26.17%
0%
26.17%
2 Years
44.9%
0%
44.9%
3 Years
31.07%
0%
31.07%
4 Years
83.26%
0%
83.26%
5 Years
75.32%
0%
75.32%
Changzhou Qianhong Biopharma Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
0.53%
EBIT Growth (5y)
28.28%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.40
Sales to Capital Employed (avg)
0.69
Tax Ratio
16.44%
Dividend Payout Ratio
42.86%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
11.99%
ROE (avg)
8.97%
Valuation key factors
Factor
Value
P/E Ratio
21
Industry P/E
Price to Book Value
3.28
EV to EBIT
17.43
EV to EBITDA
15.10
EV to Capital Employed
4.68
EV to Sales
5.04
PEG Ratio
0.32
Dividend Yield
1.78%
ROCE (Latest)
26.86%
ROE (Latest)
15.34%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
Jun'25
Jun'24
Change(%)
Net Sales
405.20
387.80
4.49%
Operating Profit (PBDIT) excl Other Income
113.50
100.10
13.39%
Interest
0.00
0.30
-100.00%
Exceptional Items
1.20
0.40
200.00%
Consolidate Net Profit
92.00
75.10
22.50%
Operating Profit Margin (Excl OI)
239.70%
212.70%
2.70%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2025 is 4.49% vs -12.91% in Jun 2024
Consolidated Net Profit
YoY Growth in quarter ended Jun 2025 is 22.50% vs 149.50% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
1,502.50
1,793.90
-16.24%
Operating Profit (PBDIT) excl Other Income
429.30
225.60
90.29%
Interest
1.50
6.20
-75.81%
Exceptional Items
3.50
1.30
169.23%
Consolidate Net Profit
333.20
178.70
86.46%
Operating Profit Margin (Excl OI)
239.20%
85.10%
15.41%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -16.24% vs -21.54% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 86.46% vs -44.14% in Dec 2023
About Changzhou Qianhong Biopharma Co., Ltd. 
Changzhou Qianhong Biopharma Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






